Summit Therapeutics Inc
NASDAQ:SMMT
Summit Therapeutics Inc
NASDAQ:SMMT
Price:
15.46
USD
-3.86%
Market Closed
Market Cap:
$12B
Balance Sheet
Balance Sheet Decomposition
Summit Therapeutics Inc
Summit Therapeutics Inc
Balance Sheet Decomposition is not available for
Summit Therapeutics Inc
Summit Therapeutics Inc
Balance Sheet
Summit Therapeutics Inc
Summit Therapeutics Inc
Currency: USD
| Jan-2018 | Jan-2019 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & Cash Equivalents |
29
|
35
|
64
|
66
|
72
|
349
|
71
|
105
|
225
|
|
| Cash Equivalents |
29
|
35
|
64
|
66
|
72
|
349
|
71
|
105
|
225
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
115
|
307
|
488
|
|
| Total Receivables |
11
|
14
|
6
|
10
|
17
|
6
|
1
|
1
|
0
|
|
| Accounts Receivables |
4
|
6
|
1
|
0
|
2
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
7
|
8
|
5
|
10
|
16
|
6
|
1
|
0
|
0
|
|
| Other Current Assets |
12
|
12
|
10
|
11
|
8
|
302
|
3
|
11
|
7
|
|
| Total Current Assets |
51
|
61
|
80
|
88
|
97
|
657
|
190
|
424
|
720
|
|
| PP&E Net |
3
|
2
|
2
|
1
|
4
|
5
|
6
|
7
|
22
|
|
| PP&E Gross |
3
|
2
|
2
|
1
|
4
|
5
|
6
|
7
|
0
|
|
| Accumulated Depreciation |
0
|
1
|
1
|
1
|
3
|
1
|
1
|
1
|
0
|
|
| Intangible Assets |
21
|
14
|
13
|
12
|
10
|
0
|
0
|
0
|
0
|
|
| Goodwill |
4
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
1
|
4
|
2
|
7
|
|
| Other Assets |
4
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
|
| Total Assets |
78
N/A
|
80
+2%
|
96
+21%
|
103
+7%
|
113
+11%
|
664
+486%
|
203
-69%
|
436
+115%
|
751
+72%
|
|
| Liabilities | ||||||||||
| Accounts Payable |
6
|
6
|
5
|
6
|
4
|
0
|
3
|
5
|
20
|
|
| Accrued Liabilities |
6
|
6
|
6
|
5
|
12
|
18
|
17
|
35
|
50
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
20
|
0
|
0
|
0
|
|
| Other Current Liabilities |
20
|
6
|
3
|
9
|
9
|
1
|
1
|
2
|
2
|
|
| Total Current Liabilities |
33
|
17
|
14
|
20
|
26
|
39
|
20
|
42
|
73
|
|
| Long-Term Debt |
4
|
0
|
0
|
0
|
0
|
495
|
100
|
0
|
0
|
|
| Deferred Income Tax |
3
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
42
|
4
|
4
|
3
|
5
|
4
|
5
|
5
|
19
|
|
| Total Liabilities |
83
N/A
|
24
-71%
|
17
-27%
|
23
+32%
|
30
+31%
|
538
+1 686%
|
125
-77%
|
47
-63%
|
92
+97%
|
|
| Equity | ||||||||||
| Common Stock |
0
|
0
|
1
|
1
|
1
|
2
|
7
|
7
|
8
|
|
| Retained Earnings |
141
|
131
|
158
|
211
|
300
|
378
|
993
|
1 215
|
2 294
|
|
| Additional Paid In Capital |
141
|
191
|
241
|
293
|
384
|
505
|
1 066
|
1 598
|
2 948
|
|
| Other Equity |
4
|
5
|
5
|
4
|
2
|
2
|
2
|
2
|
3
|
|
| Total Equity |
5
N/A
|
56
N/A
|
79
+41%
|
80
+1%
|
83
+5%
|
127
+52%
|
78
-39%
|
389
+400%
|
659
+69%
|
|
| Total Liabilities & Equity |
78
N/A
|
80
+2%
|
96
+21%
|
103
+7%
|
113
+11%
|
664
+486%
|
203
-69%
|
436
+115%
|
751
+72%
|
|
| Shares Outstanding | ||||||||||
| Common Shares Outstanding |
15
|
32
|
67
|
83
|
98
|
211
|
702
|
738
|
775
|
|
Switch to:
Switch to:
See Also
Discover More
